Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential
anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for …

Background: We performed an individual patient data meta-analysis to examine the impact
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …

Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods In …

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …

PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …

PURPOSE: A phase III study was performed to determine whether concurrent or sequential
treatment with radiotherapy (RT) and chemotherapy (CT) improves survival in unresectable …

Background Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell
lung cancer. In a phase 2 study of irinotecan plus cisplatin in patients with extensive small…

Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …

Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression-free …

PURPOSE: To evaluate the optimal timing for thoracic radiotherapy (TRT) in limited-stage
small-cell lung cancer (LS-SCLC), the Lung Cancer Study Group of the Japan Clinical …